An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder

NCT01038128 | Completed Results

• 1 other identifier: 2009-P-001901
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of this 13-week clinical trial is to test the hypothesis that treatment with Memantine will significantly improve the symptoms of those suffering from either bulimia nervosa, purging type or suffering from body dysmorphic disorder.

Conditions

Bulimia Nervosa; Body Dysmorphic Disorder

Keywords

Bulimia nervosa; Bulimia; Body dysmorphic disorder; Eating disorders; Body image; Binge eating; purging

Outcome Measures

Primary Outcomes (5)

• Number of Binge Eating and Self-induced Vomiting Episodes

  Number of self-reported binge eating and self-induced vomiting episodes during the week prior to the Baseline and Endpoint Visits.

  Baseline to 12 weeks

• Ratings of Eating Pathology

  Ratings obtained from the self-induced vomiting and laxative misuse sections of the Eating Disorder Examination. The scale asks participants to calculate discreet episodes of self-induced vomiting and laxative misuses over the period of four weeks. Generally, the value obtained is the number of occurrences. However, in cases where the number of occurrences was too great to be calculated, the number "777" was used. The scale is therefore open-ended, with higher numbers coinciding with a greater number of episodes.

  Baseline to 12 weeks

• Clinical Global Impression Scale

  Disorder severity is measured based on the Clinical Global Impression Scale. The scale ranges from 1 unit (Not at all ill) to 7 units (extremely ill).

  Baseline to 12 weeks

• Body Dysmorphic Disorder Version of the Yale Brown Obsessive Compulsive Scale

  The scale ranges from 0 to 91 units, with 0 representing the least ill and 91 representing the most ill.

  Baseline to 12 weeks

• Brown Assessments of Belief Scale

  The range for this scale is 0 to 28 units, with 0 representing the least ill and 28 representing the most ill.

  Baseline to 12 weeks

Study Arms (1)

Memantine

EXPERIMENTAL

Memantine, 10-40 mg daily

Drug: Memantine

Interventions

Memantine DRUG

Drug: Memantine, 10-40 mg daily

Also known as: Namenda

Memantine

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants must meet DSM-IV criteria for a current diagnosis of bulimia nervosa as determined by the Structured Clinical Interview for DSM-IV (SCID) and Eating Disorder Examination (EDE).
• Participants must report an average of 3 or more binges and vomiting episodes per week in the 2-week period prior to the screening visit.
• Male or Female between 18 and 65 years of age, inclusive.
• Female participants must be: postmenopausal for at least one year, surgically sterile, or practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization, abstinence and agreeing to continue abstinence or to use one of the acceptable methods of contraception just enumerated should sexual activity commence) before entry and throughout the study; and have a negative serum pregnancy test at the screening visit.
• Participants must have observed a designated washout period of at least seven days or a period equal to five half-lives of prohibited medications.
• Participants must be able to take oral medication, adhere to the medication regimens, and be willing to return for regular visits.
• Participants must be able and willing to read and comprehend written instructions and comprehend and complete all scales and questionnaires required by the protocol.
• Participants must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
• Participants must meet DSM-IV criteria for a current diagnosis of body dysmorphic disorder as determined by the SCID.
• Participants must exhibit a score of ≥ 20 on the Body Dysmorphic Disorder Version of the Yale Brown Obsessive Compulsive Scale (BDD-YBOCS) at a score of ≥ 5 on the first three items of the BDD-YBOCS, which are the items that assess the DSM-IV criteria for Body Dysmorphic Disorder.

You may not qualify if:

• Participants with a lifetime diagnosis of schizophrenia, other psychotic disorder, or bipolar disorder as defined by DSM-IV and supported by the SCID.
• Participants with clinically significant current depression or who, in the investigators' judgment, might require intervention with either pharmacological or non-pharmacological therapy for major depressive disorder over the course of the study.
• Participants judged clinically to be at suicidal or homicidal risk by the study physician.
• Participants meeting DSM-IV criteria for any form of substance dependence or abuse (with the exception of nicotine or caffeine dependence) within 3 months prior to the screening visit.
• Participants meeting DSM-IV criteria for anorexia nervosa within 3 months prior to the screening visit.
• Participants with a current DSM-IV diagnosis of an organic mental disorder.
• Participants who have begun to receive formal psychotherapy (cognitive-behavioral therapy, interpersonal therapy or self-guided cognitive-behavioral therapy) for bulimia nervosa within 6 months prior to the screening visit.
• Participants who display a positive urine screen for drugs of abuse (phencyclidine, cocaine, amphetamines, tetrahydrocannabinol, and opiates) at the screening visit.
• Participants who have previously received memantine for any reason.
• Participants who have received an investigational medication within 30 days of the screening visit.
• Participants who are pregnant or lactating.
• Participants with a body mass index (BMI) less than 18.5 or greater than 35.
• Participants who have abused ipecac as a method of purging within the past 2 years.
• Participants who exhibit a serum potassium level of less than 3.0 mEq/L.
• Participants with thyroid-stimulating hormone concentrations outside the range of 0.5-5.0 lU/mL.

Sponsors & Collaborators

• Mclean Hospital: lead

Study Sites (1)

McLean Hospital

Belmont, Massachusetts, 02478, United States

Location

MeSH Terms

Conditions

Bulimia Nervosa; Body Dysmorphic Disorders; Bulimia; Feeding and Eating Disorders

Interventions

Memantine

Condition Hierarchy (Ancestors)

Mental Disorders; Somatoform Disorders; Hyperphagia; Signs and Symptoms, Digestive; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Amantadine; Adamantane; Bridged-Ring Compounds; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals

Results Point of Contact

• Title: Study Coordinator
• Organization: McLean Hospital

eryan@mclean.harvard.edu

617-855-2984

Study Officials

• James I Hudson, M.D., Sc.D.

  Mclean Hospital

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Psychiatry, Harvard Medical School

Study Record Dates

• First Submitted: December 21, 2009
• First Posted: December 23, 2009
• Study Start: December 1, 2009
• Primary Completion: May 1, 2011
• Study Completion: May 1, 2011
• Last Updated: May 4, 2015
• Results First Posted: June 12, 2012

Record last verified: 2015-04

Locations

US (1)